GLENMARK PHARMACEUTICALS LTD.

Glenmark Pharmaceuticals Inc., USA has announced the launch of Calcium Gluconate Injection USP in multiple dosage forms: 1,000 mg/10 mL, 5,000 mg/50 mL Single-Dose Vials, and 10,000 mg/100 mL Pharmacy Bulk Package. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi USA's Calcium Gluconate Injection. The U.S. market for this injection achieved approximately $69.9 million in sales for the 12 months ending June 2026, according to IQVIA data. This launch strengthens Glenmark's U.S. injectables business and hospital portfolio, aligning with their strategy to build a differentiated and sustainable injectables business.

Glenmark Pharmaceuticals Limited has received U.S. FDA approval for its Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. This product is bioequivalent and therapeutically equivalent to Flonase® Nasal Spray, 0.05 mg/spray, a reference drug by Haleon US Holdings LLC. The nasal spray will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. The market for Flonase® Nasal Spray achieved approximately $295.2 million in annual sales for the 12 months ending June 2026, according to IQVIA® sales data. This approval signifies an expansion of Glenmark's respiratory portfolio in the U.S., aiming to provide affordable treatment options.

Glenmark Pharmaceuticals Ltd is sending letters to shareholders whose email addresses are not registered, providing a web link and QR code to access the Integrated Annual Report and AGM Notice for FY 2025-26. This communication is in compliance with SEBI Listing Regulations. The 48th Annual General Meeting is scheduled for September 11, 2026, to be held via Video Conference. Shareholders can opt for permanent email registration for future communications.

Glenmark Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Reporting (BRSR) for the Financial Year 2025-26, as per SEBI regulations. The report details the company's corporate identity, registered and corporate addresses, and contact information for queries. It outlines the company's business activities, primarily focused on pharmaceuticals, encompassing research & development, manufacturing, and sales of generics, specialty medications, and OTC treatments across various therapeutic areas. The reporting boundary is standalone unless otherwise stated. The company operates 8 plants and 19 offices nationally, and 3 plants and 48 offices internationally, serving 28 states and 8 union territories in India and over 80 countries globally. Exports contributed 57.99% of the total standalone turnover.

Glenmark Pharmaceuticals Limited has announced its 48th Annual General Meeting (AGM) will be held on Friday, September 11, 2026, at 2:00 p.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in compliance with MCA and SEBI regulations. The company has also released its Integrated Annual Report, including BRSR for the Financial Year 2025-26, which is available on the company's website and NSDL's e-voting portal. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY26, declaration of a dividend of INR 2.50 per equity share, re-appointment of Mrs. Blanche Saldanha as a Non-Executive Director, and ratification of the Cost Auditor's remuneration for FY27.

Glenmark Pharmaceuticals Limited has announced its 48th Annual General Meeting (AGM) will be held on Friday, September 11, 2026, at 2:00 p.m. IST via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The meeting will cover ordinary business including the adoption of audited standalone and consolidated financial statements for the Financial Year ended March 31, 2026, and the declaration of a dividend of INR 2.50 per equity share. Special business includes the re-appointment of Mrs. Blanche Saldanha as a Non-Executive Director and ratification of remuneration for the Cost Auditor, M/s. R A & Co., for the Financial Year ending March 31, 2027. The notice of the AGM is available on the company's website and NSDL's e-voting portal.

Glenmark Pharmaceuticals Ltd. announced that its subsidiary, Glenmark Pharmaceuticals Inc., USA, has entered into a settlement agreement with Humana, Inc. for $15.28 million to resolve antitrust and consumer protection lawsuits. These lawsuits, consolidated in the Eastern District of Pennsylvania, alleged price-fixing and anti-competitive conduct related to generic pharmaceutical products. Glenmark USA denies all allegations, and the settlement does not constitute an admission of liability. The full settlement amount has been provided for in the company's financials and is not expected to have a significant impact on the company's financial position.

Glenmark Pharmaceuticals Ltd. reported a strong first quarter for FY27, with consolidated revenue soaring by 23.1% year-on-year to ₹40,185 million. This growth was driven by robust performance across key markets, including a 15.5% rise in India Formulations, a significant 41.1% surge in North America (partially due to deferred out-licensing income), and strong double-digit growth in Europe and Emerging Markets. EBITDA increased by 38.6% to ₹8,048 million, with an improved EBITDA margin of 20.03%. Profit After Tax (PAT) stood at ₹4,828 million, reflecting a PAT margin of 11.8%. The company highlighted broad-based growth and strong execution, with Chairman & Managing Director Glenn Saldanha expressing confidence in strengthening core businesses and expanding specialty and innovation-led platforms.

Glenmark Pharmaceuticals Ltd. has announced amendments to its Policy on Determination of Materiality for Disclosures, approved by the Board of Directors on July 31, 2026. The company has also designated specific officials authorized to determine the materiality of events or information and make necessary disclosures to the stock exchanges as per SEBI regulations. This move ensures compliance and transparency in corporate communication.

Glenmark Pharmaceuticals Ltd announced that its Board of Directors has approved the financial results for the quarter ended June 30, 2026, and set Monday, August 31, 2026, as the record date for determining dividend entitlement. The 48th Annual General Meeting (AGM) will be held on September 11, 2026. The company also approved amendments to several policies including Related Party Transactions, Materiality for Disclosures, Insider Trading, Dividend Distribution, and Nomination and Remuneration. Additionally, the Risk Management Committee has been reconstituted, with Ms. Patricia Andrews appointed as Chairperson, effective August 1, 2026. The company reported unaudited standalone and consolidated financial results for the quarter.